Meningioma, glioma, glioblastoma and neurofibromatosis can be effectively suppressed and controlled by proinsulin C-peptide

Author: Gabor Varga
13.11.2018

Neurofibromatosis type 2 is a disorder characterized by the growth of noncancerous tumors in the nervous system. The most common tumors associated with neurofibromatosis type 2 are called vestibular schwannomas or acoustic neuromas. It may lead to hearing and sight loss, facial paralysis.
https://ghr.nlm.nih.gov/condition/neurofibromatosis-type-2 I have met this disease among the frequent characteristics of Ring chromosome 22 as a subtype of deletion 22q13. Ring 22 is unstable and so it may loose the NF2 gene making the subjects susceptible to develop neurofibromatosis, supposed the NF2 gene on the second chromosome is also damaged in some way (second hit).
https://www.ncbi.nlm.nih.gov/pubmed/21175598
The “second hit” may be caused also by inflammation especially in the case of deletion 22q13 or EHBOS (see. Point 11.and 17. in www.ehbos.com)

The progression of this disease can be effectively treated by inhibiting the Transforming Growth Factor beta Receptor I. (TGF-beta) :
https://www.ncbi.nlm.nih.gov/pubmed/30135214 
This can be achieved by administration of intranasal proinsulin C-peptide (www.cpeptide.com), because this peptide is a potent suppressor of TGF-beta receptor signaling:
https://www.ncbi.nlm.nih.gov/pubmed/19091788

What is more, this peptide seems to inhibit the development of meningioma, glioma, glioblastoma generally. How do we know this?

Individuals, who have unusually high levels of proinsulin c-peptide in the blood that may be the case due to prediagnostic diabetes or diabetes have decreased risk of the above mentioned brain tumors in spite of the fact that high insulin or blood sugar levels generally promote tumor development:
https://www.ncbi.nlm.nih.gov/pubmed/27253176
https://www.ncbi.nlm.nih.gov/pubmed/28469238
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767232/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3947107/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826220/
https://www.ncbi.nlm.nih.gov/pubmed/29531326

For more information see:
www.cpeptide.com
www.ehbos.com

FDA Compliance

The information on this website has not been evaluated by the Food & Drug Administration or any other medical body. We do not aim to diagnose, treat, cure or prevent any illness or disease. Information is shared for educational purposes only. You must consult your doctor before acting on any content on this website, especially if you are pregnant, nursing, taking medication, or have a medical condition.